BR112012020855B8 - método para produzir um conjugado de biomolécula - Google Patents

método para produzir um conjugado de biomolécula

Info

Publication number
BR112012020855B8
BR112012020855B8 BR112012020855A BR112012020855A BR112012020855B8 BR 112012020855 B8 BR112012020855 B8 BR 112012020855B8 BR 112012020855 A BR112012020855 A BR 112012020855A BR 112012020855 A BR112012020855 A BR 112012020855A BR 112012020855 B8 BR112012020855 B8 BR 112012020855B8
Authority
BR
Brazil
Prior art keywords
producing
biomolecule conjugate
biomolecule
conjugate
biomolecules
Prior art date
Application number
BR112012020855A
Other languages
English (en)
Other versions
BR112012020855A2 (pt
BR112012020855B1 (pt
Inventor
Lucia Bianco Carolina
Shung Brian To Chi
H Vogel Jens
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BR112012020855A2 publication Critical patent/BR112012020855A2/pt
Publication of BR112012020855B1 publication Critical patent/BR112012020855B1/pt
Publication of BR112012020855B8 publication Critical patent/BR112012020855B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025—Reverse osmosis; Hyperfiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

método para ativação e conjugação de biomoléculas. a presente invenção refere-se a um método para produzir um conjugado de biomolécula, onde o método é integrado em uma única operação unitária.
BR112012020855A 2010-02-21 2011-02-21 método para produzir um conjugado de biomolécula BR112012020855B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30651310P 2010-02-21 2010-02-21
US61/306,513 2010-02-21
PCT/US2011/025592 WO2011103531A1 (en) 2010-02-21 2011-02-21 Method for Activation and Conjugation of Biomolecules

Publications (3)

Publication Number Publication Date
BR112012020855A2 BR112012020855A2 (pt) 2017-08-29
BR112012020855B1 BR112012020855B1 (pt) 2021-05-04
BR112012020855B8 true BR112012020855B8 (pt) 2021-05-25

Family

ID=44483343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020855A BR112012020855B8 (pt) 2010-02-21 2011-02-21 método para produzir um conjugado de biomolécula

Country Status (35)

Country Link
US (1) US9254336B2 (pt)
EP (1) EP2536399B1 (pt)
JP (1) JP5726915B2 (pt)
KR (1) KR101776976B1 (pt)
CN (2) CN102970988B (pt)
AU (1) AU2011217794B2 (pt)
BR (1) BR112012020855B8 (pt)
CA (1) CA2790401C (pt)
CL (1) CL2012002306A1 (pt)
CO (1) CO6592111A2 (pt)
CR (1) CR20120437A (pt)
CU (1) CU20120121A7 (pt)
CY (1) CY1122711T1 (pt)
DK (1) DK2536399T3 (pt)
EA (1) EA201290804A1 (pt)
EC (1) ECSP12012112A (pt)
ES (1) ES2769629T3 (pt)
GT (1) GT201200244A (pt)
HK (2) HK1182330A1 (pt)
HR (1) HRP20192164T1 (pt)
HU (1) HUE047661T2 (pt)
IL (1) IL221447A (pt)
LT (1) LT2536399T (pt)
MX (1) MX2012009674A (pt)
NZ (1) NZ601905A (pt)
PE (1) PE20130003A1 (pt)
PH (1) PH12016501602A1 (pt)
PL (1) PL2536399T3 (pt)
PT (1) PT2536399T (pt)
RS (1) RS59827B1 (pt)
SG (1) SG183309A1 (pt)
SI (1) SI2536399T1 (pt)
UA (1) UA115221C2 (pt)
WO (1) WO2011103531A1 (pt)
ZA (2) ZA201206215B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE481323A (pt) * 1947-04-10
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
CN106104273A (zh) 2013-12-12 2016-11-09 施特姆森特克斯股份有限公司 新型抗dpep3抗体和使用方法
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
CA2491310C (en) * 2002-07-15 2015-10-06 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
ES2308032T5 (es) 2002-12-31 2017-04-24 Nektar Therapeutics Derivados poliméricos de ácido maleámico y sus bioconjugados
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2006053299A2 (en) * 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
US20070173634A1 (en) 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
JP5908401B2 (ja) * 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
CN107412754A (zh) * 2009-12-22 2017-12-01 塞尔德克斯医疗公司 疫苗组合物

Also Published As

Publication number Publication date
US20130040362A1 (en) 2013-02-14
CA2790401A1 (en) 2011-08-25
PL2536399T3 (pl) 2020-06-29
LT2536399T (lt) 2020-03-10
KR101776976B1 (ko) 2017-09-08
ES2769629T3 (es) 2020-06-26
CN105664175A (zh) 2016-06-15
CN105664175B (zh) 2019-07-23
EP2536399A4 (en) 2016-02-24
CR20120437A (es) 2012-12-07
RS59827B1 (sr) 2020-02-28
CU20120121A7 (es) 2013-01-30
HRP20192164T1 (hr) 2020-03-06
CN102970988B (zh) 2016-03-16
AU2011217794A1 (en) 2012-09-20
PE20130003A1 (es) 2013-01-19
ZA201405941B (en) 2018-05-31
IL221447A (en) 2015-09-24
NZ601905A (en) 2014-09-26
ECSP12012112A (es) 2012-10-30
CO6592111A2 (es) 2013-01-02
PH12016501602A1 (en) 2017-06-05
IL221447A0 (en) 2012-10-31
GT201200244A (es) 2014-09-02
CN102970988A (zh) 2013-03-13
AU2011217794B2 (en) 2015-01-29
CL2012002306A1 (es) 2013-01-18
DK2536399T3 (da) 2020-02-10
PT2536399T (pt) 2020-02-06
HUE047661T2 (hu) 2020-05-28
HK1225652A1 (zh) 2017-09-15
WO2011103531A1 (en) 2011-08-25
EP2536399A1 (en) 2012-12-26
JP5726915B2 (ja) 2015-06-03
MX2012009674A (es) 2012-09-07
ZA201206215B (en) 2014-10-29
US9254336B2 (en) 2016-02-09
CA2790401C (en) 2018-05-29
BR112012020855A2 (pt) 2017-08-29
SI2536399T1 (sl) 2020-02-28
UA115221C2 (uk) 2017-10-10
CY1122711T1 (el) 2021-03-12
JP2013520441A (ja) 2013-06-06
EP2536399B1 (en) 2019-11-20
KR20120120966A (ko) 2012-11-02
SG183309A1 (en) 2012-09-27
EA201290804A1 (ru) 2013-03-29
HK1182330A1 (zh) 2013-11-29
BR112012020855B1 (pt) 2021-05-04

Similar Documents

Publication Publication Date Title
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BR112012020855B8 (pt) método para produzir um conjugado de biomolécula
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
BRPI1011005A2 (pt) anticorpos anti-epcam
GB201103836D0 (en) Conjugation process
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
BR112012033107A2 (pt) derivados de insulina contendo ligações dissulfeto adicionais.
FI20126341A (fi) Menetelmä mikrofibrilloidun selluloosan valmistamiseksi, josta vesi on poistettu
BR112012005592A2 (pt) geração de sementes oleaginosas produzindo alto poliidroxibutirato.
FR2960354B1 (fr) Dispositif de production de très hautes fréquences par battement de fréquences lumineuses.
EP3019532A4 (en) CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
UY34902A (es) Forma cristalina de un derivado de indolinona y su uso
EP2990114A4 (en) Method for producing catalyst for cyclic carbonate synthesis
IT1397886B1 (it) Procedimento per la produzione di componenti di carburanti per autotrazione.
BR112013029459A2 (pt) turbina, método de operar uma turbina e veículo
BR112012026542A2 (pt) abordagem seletiva de tecido
BR112013024193A2 (pt) método para a produção de uma estrutura útil para a produção de um gerador termelétrico, estutura útil, gerador termelétrico
BR112012029626A2 (pt) processo para preparar ditianona-tetracarboxi-dimidas
BR112013025764A2 (pt) dispositivo impulsionador
EA201391563A1 (ru) Твердое вещество полихлоропрен с тиксотропными свойствами
FR2987092B1 (fr) Ensemble de reducteurs.
BR112012004828A2 (pt) transportador de pentose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF